ClinVar Miner

Submissions for variant NM_130837.3(OPA1):c.1035+4T>C

gnomAD frequency: 0.88294  dbSNP: rs166850
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 14
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
GeneDx RCV000081773 SCV000170836 benign not specified 2012-10-22 criteria provided, single submitter clinical testing This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease.
Eurofins Ntd Llc (ga) RCV000081773 SCV000203167 benign not specified 2014-01-23 criteria provided, single submitter clinical testing
PreventionGenetics, part of Exact Sciences RCV000081773 SCV000315377 benign not specified criteria provided, single submitter clinical testing
Illumina Laboratory Services, Illumina RCV000576690 SCV000442622 benign Autosomal dominant optic atrophy classic form 2018-01-12 criteria provided, single submitter clinical testing This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score and internal cut-off values, a variant classified as benign is not then subjected to further curation. The score for this variant resulted in a classification of benign for this disease.
Athena Diagnostics RCV000576690 SCV000677374 benign Autosomal dominant optic atrophy classic form 2017-04-27 criteria provided, single submitter clinical testing
ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories RCV000676694 SCV001156722 benign not provided 2023-11-29 criteria provided, single submitter clinical testing
Invitae RCV000676694 SCV001718736 benign not provided 2024-02-01 criteria provided, single submitter clinical testing
Genome-Nilou Lab RCV001787898 SCV002029297 benign Mitochondrial DNA depletion syndrome 14 (cardioencephalomyopathic type) 2021-09-05 criteria provided, single submitter clinical testing
Genome-Nilou Lab RCV001787897 SCV002029298 benign Abortive cerebellar ataxia 2021-09-05 criteria provided, single submitter clinical testing
Genome-Nilou Lab RCV000576690 SCV002029299 benign Autosomal dominant optic atrophy classic form 2021-09-05 criteria provided, single submitter clinical testing
Genome-Nilou Lab RCV001787896 SCV002029300 benign Optic atrophy with or without deafness, ophthalmoplegia, myopathy, ataxia, and neuropathy 2021-09-05 criteria provided, single submitter clinical testing
Mayo Clinic Laboratories, Mayo Clinic RCV000676694 SCV000802491 benign not provided 2016-02-19 no assertion criteria provided clinical testing
Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen RCV000081773 SCV001743935 benign not specified no assertion criteria provided clinical testing
Joint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+ RCV000081773 SCV001957766 benign not specified no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.